Fosfomycin or Nitrofurantoin for a Bladder Infection?Two Trials and the Dose Difference

One packet of medicine can look easier than several days of capsules. For a bladder infection, the useful comparison includes how many women recovered, when recovery was measured and which dose was tested. Two large trials provide those details, while newer pooled evidence makes a blanket ranking harder to defend.

The 2018 trial measured sustained resolution

Researchers randomized 513 nonpregnant women in Switzerland, Poland and Israel to nitrofurantoin, 100 mg three times daily for five days, or one 3-gram fosfomycin dose. Participants had urinary symptoms and a positive dipstick.¹

At the assessment 28 days after treatment completion, clinical resolution occurred in 171 of 244 women (70%) with nitrofurantoin and 139 of 241 (58%) with fosfomycin. The difference was 12 percentage points, with a 95% confidence interval of 4–21 points. Resolution required complete disappearance of symptoms and signs without an earlier treatment failure. This was more demanding than feeling somewhat better.¹

Patients knew their treatment, which could influence reporting. Pregnancy, breastfeeding, suspected upper urinary infection and several complicating conditions were excluded. The study does not settle treatment for those situations.¹

The SCOUT trial measured recovery at day seven

The 2026 SCOUT trial² randomized 768 women at 34 Spanish primary-care centers to four regimens. Its nitrofurantoin arm also used 100 mg three times daily for five days. The other arms used one fosfomycin dose, two doses or three-day pivmecillinam.²

Among 720 women with primary-outcome data, all infection symptoms had disappeared by day seven in 128 of 172 (74%) taking nitrofurantoin and 109 of 185 (59%) taking single-dose fosfomycin. The difference was 15.5 percentage points, with a 95% confidence interval of 5.9–25.1 points, and was statistically significant after adjustment for multiple comparisons.²

The two-dose fosfomycin comparison did not reach statistical significance. That is insufficient evidence to promise that an extra packet fixes the problem.²

SCOUT was open-label and recruited fewer than the planned 1,120 participants. Only 57% of available baseline cultures confirmed infection; others were negative or contaminated. Missing outcomes and one-month follow-up limit interpretation. Exclusions included pregnancy, breastfeeding and recurrent UTIs: at least three in a year or two in six months.²

A new review separates doses and populations

A review published October 8, 2026 pooled six randomized trials with 1,762 participants, including pregnant and nonpregnant women. Its search ended May 9, 2025, before SCOUT’s results were published.³

The abstract reports similar pooled clinical cure results overall, but higher cure with 300 mg/day nitrofurantoin at 14 and at least 28 days. The 200 mg/day subgroup showed no significant difference. Overall adverse-reaction rates did not differ significantly, although reactions were more frequent in the 300 mg/day subgroup.³

We could verify the publisher’s abstract and reference list; the complete review requires subscription access. Those subgroup findings do not establish that increasing a woman’s dose improves her outcome. They compare evidence across trials with different participants and regimens.³

Check the formulation before comparing schedules

The 2026 European Association of Urology⁴ guidance still includes both fosfomycin and nitrofurantoin among first-line options for cystitis in women. For nitrofurantoin monohydrate/macrocrystals or prolonged-release macrocrystals, it lists 100 mg twice daily for five days. Other formulations have other schedules.⁴

The three-times-daily trial regimen therefore should not become an instruction to add a capsule to your prescription. Ask the pharmacist to confirm the formulation, number of doses each day and course length on your own label.

EAU⁴ says antibiotic selection should consider bacterial susceptibility, efficacy, adverse reactions, cost and availability. Kidney function can also affect suitability. Bring previous urine-culture results, antibiotic reactions and any known kidney disease to the prescribing conversation.⁴

Agree on what happens if symptoms persist

The U.S. label for fosfomycin oral granules advises against more than one single dose for a single acute-cystitis episode. It says repeated daily dosing did not improve success in the evidence underlying the label and increased adverse events. Do not take another sachet on your own because burning remains.⁵

Tell the pharmacist if you take metoclopramide: the label says it lowers fosfomycin concentrations and urinary excretion. The same label does not indicate oral fosfomycin for kidney infection.⁵

In England’s NICE⁶ guidance, symptoms that worsen rapidly or significantly, or do not start improving within 48 hours of an antibiotic, need reassessment. A urine sample for culture and susceptibility testing is advised if not already obtained.⁶

NIDDK⁷ says kidney-infection symptoms can include fever and chills, pain in the back, side or groin, and nausea or vomiting. Seek care right away for that pattern. The 48-hour review point does not mean waiting through those symptoms.⁷

Before leaving the appointment, ask: “Who do I contact if this does not start helping, and do you want a urine sample before any replacement antibiotic?” Write the contact and review time beside the prescription details.

Our nitrofurantoin breathing-warning article covers a separate medicine-safety question. Chapter 9 of Laugh, Sneeze, Jump includes recording burning, infections and their start dates alongside bladder symptoms, useful details to bring when urgency and repeated infections need discussion.